Close
Help




JOURNAL

Clinical Medicine Insights: Blood Disorders

36,718 Journal Article Views | Journal Analytics

Safety and Efficacy of Argatroban in the Management of Heparin-Induced Thrombocytopenia

Submit a Paper



Publication Date: 28 Jul 2011

Journal: Clinical Medicine Insights: Blood Disorders

Citation: Clinical Medicine Insights: Blood Disorders 2011:4 11-19

doi: 10.4137/CMBD.S5118

Abstract

Heparin-induced thrombocytopenia (HIT) is a life-threatening adverse reaction to heparin therapy that is characterized by thrombocytopenia and an increased risk of venous and arterial thrombosis. According to guidelines, in patients with strongly suspected or confirmed HIT all sources of heparin have to be discontinued and an alternative, nonheparin anticoagulant for HIT treatment must immediately be started. For both the prophylaxis of thrombembolic events in HIT and the treatment of HIT with thrombosis the direct thrombin inhibitor argatroban is approved in the United States. The objective of this review is to describe the mechanism of action and the pharmacokinetic profile of argatroban, to characterize argatroban regarding its safety and therapeutic efficacy and to discuss its place in therapy in HIT.


Downloads

PDF  (468.75 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)






What Your Colleagues Say About Libertas Academica
This was the most efficient and user-friendly publishing process I have experienced.  The editorial team at Libertas Academica was phenomenal.  They kept me engaged with each step of the publishing process and they were timely and professional with their response to my inquiries.  I look forward to publishing additional articles with Libertas Academica in the future.
Dr Kevin Bain (PharmD, MPH, BCPS, CGP, CPH, FASCP, Philadelphia, PA, USA)
More Testimonials

Quick Links


New article and journal news notification services